RLFZ Stock Overview
A biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Relief Therapeutics Holding SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 2.12 |
| 52 Week High | CHF 7.22 |
| 52 Week Low | CHF 1.06 |
| Beta | 4.76 |
| 1 Month Change | -13.19% |
| 3 Month Change | -38.83% |
| 1 Year Change | 69.80% |
| 3 Year Change | -99.98% |
| 5 Year Change | n/a |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| RLFZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -7.9% | -2.5% | 0.2% |
| 1Y | 69.8% | -14.9% | -0.07% |
Return vs Industry: RLFZ exceeded the UK Biotechs industry which returned -13.2% over the past year.
Return vs Market: RLFZ exceeded the UK Market which returned 0.1% over the past year.
Price Volatility
| RLFZ volatility | |
|---|---|
| RLFZ Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: RLFZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: RLFZ's weekly volatility has decreased from 20% to 10% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 31 | n/a | www.relieftherapeutics.com |
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium phenylbutyrate for the treatment of urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria. It also develops RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome and certain chronic lung diseases, including sarcoidosis, berylliosis, and checkpoint inhibitor-induced pneumonitis.
Relief Therapeutics Holding SA Fundamentals Summary
| RLFZ fundamental statistics | |
|---|---|
| Market cap | CHF 26.47m |
| Earnings (TTM) | -CHF 17.12m |
| Revenue (TTM) | CHF 8.42m |
3.1x
P/S Ratio-1.5x
P/E RatioIs RLFZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RLFZ income statement (TTM) | |
|---|---|
| Revenue | CHF 8.42m |
| Cost of Revenue | CHF 2.58m |
| Gross Profit | CHF 5.84m |
| Other Expenses | CHF 22.96m |
| Earnings | -CHF 17.12m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Aug 29, 2025
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 69.41% |
| Net Profit Margin | -203.39% |
| Debt/Equity Ratio | 0% |
How did RLFZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 06:26 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Relief Therapeutics Holding SA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexandre Müller | Research Dynamics |
| Bob Pooler | ValuationLAB AG |